Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Cybin Inc N.CYBN

Alternate Symbol(s):  CYBN

Healthcare Drug Manufacturers - Specialty & Generic
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary... see more

NEO:CYBN - Post Discussion

Cybin Inc > Overview of Adelia Science Team that brings value to Cybin
View:
Post by Streetbrain on Dec 13, 2020 2:45pm

Overview of Adelia Science Team that brings value to Cybin

Alex Nivorozhkin, PhD. - https://www.researchgate.net/profile/Alex_Nivorozhkin

Michael G. Palfreyman, PhD, DSc - Michael is a co-inventor on 43 issued patents and co-author of more than 150 publications. Michael holds a D.Sc. (1996) in rational design of CNS drugs; a Ph.D. (1970) degree in Neuroscience and Neuropharmacology, as well as a B. Pharm (Magna Laude, 1967 in Pharmacy), and MRPharmS (Pharmacy Practice, 1971), .

Alex Belser, PhD -https://alexbelser.com/work.html

Clinton E. Canal, PhD -https://www.researchgate.net/profile/Clinton_Canal

Brett J. Greene -  https://bouve.northeastern.edu/bchs/directory/brett-greene/

Comment by realitycheck00 on Dec 14, 2020 8:30am
One week after they announced the agreement they have officially closed !!!!     https://www.businesswire.com/news/home/20201214005385/en/CYBIN-Closes-Acquisition-of-Adelia-Therapeutics-Bolsters-Scientific-Team-and-Grows-IP-Portfolio-to-7-Patent-Filings
Comment by rpthethird on Dec 14, 2020 9:10am
wow, that was a fast close!
Comment by realitycheck00 on Dec 14, 2020 4:16pm
Cybin looking good.  Seems like 3rd largest market cap aside from Compass and MindMed.
Comment by Jim1274 on Dec 14, 2020 11:56pm
Looks like an uplisting application was filled today... was filled in Ontario, not sure of if they can apply through Ontario for the Nasdaq or maybe the TSX?? 
Cybin Inc
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities